Hatice Bölek (@hatice_bolek) header
Hatice Bölek (@hatice_bolek) profile picture

MD | Medical Oncologist | Alumni @Hacettepe1967 @AnkaraUni | 2024 ASCO IDEA awardee | #cat lover

Türkiye
Joined August 2018
Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)Photo by Hatice Bölek (@hatice_bolek)
Our review on DDIs in prostate Ca is now published @ESMO_Open! @coskunyazgann Thanks to @DrYukselUrun @Silke_Gillessen @DrRanaMcKay @yekeduz_emre and Marina Kaymakcalan for their support. authors.elsevier.com/sd/arti…
1
24
2
74
28,204
Hatice Bölek retweeted
VOLGA: OS benefit without adjuvant EV. Do we really need EV after surgery? An important question for future trials. Proud to have contributed to this study. @myESMO @OncoAlert @OpenMedicineHQ #ESMO26 @tompowles1 @Uromigos @urologysummit
13
41
1,611
Hatice Bölek retweeted
Availability is not access. Proud to lead our ARON-AID study: revealing major gaps in kidney cancer treatment access across 58 countries. Grateful to all our collaborators for this truly global effort. How can we close this gap? @OncJournal @OncoAlert @OpenMedicineHQ @KidneyCancer @kidneycan @IKCCorg @ASCO @myESMO @urologysummit
2
13
50
1,291
New ESMO Guideline on Cervical Cancer 🔹 Less invasive surgery in early-stage disease: following SHAPE, simple hysterectomy is recommended for selected low-risk tumors ≤2 cm. For tumors <4 cm, SLNB is now the preferred method of LN staging. 🔹 Even with negative imaging, para-aortic LN metastases may be present in 8–12% of LACC, imaging sensitivity %33-62 🔹 INTERLACE was positive, but induction chemotherapy is recommended only when IMRT/VMAT and/or IGABT are unavailable. 🔹 HRT >> part of survivorship care for premenopausal women. @myESMO esmoopen.com/action/showPdf?…
1
8
355
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial thelancet.com/journals/lance…
1
6
807
📣📣📣 Calling all trainees at #ASCO26! Face off against other teams of trainees from across the globe to test your Medical Oncology knowledge in this team trivia event! Date: Friday, May 29 Time: 2:30PM – 3:45PM CT Location: Trainee & Early Career Lounge
10
35
1,889
Hatice Bölek retweeted
Our new international real-world validation of the Meet-URO score in 1,418 first-line mRCC patients is out in @TOncologist. Read here: doi.org/10.1093/oncolo/oyag2… #OncTwitter #KidneyCancer #mRCC #PrecisionMedicine
1
4
11
793
📣 Sac-TMT demonstrated improved OS and PFS compared with chemotherapy in advanced/recurrent endometrial cancer previously treated with platinum-based chemotherapy and anti-PD-1/L1 immunotherapy! A new option in a setting with limited treatment options.
1
6
360
Hatice Bölek retweeted
Happy to see our work cited at APCCC. ARPI selection in older patients is not only efficacy. Drug interactions, comorbidities, and daily medications matter. @hatice_bolek @yekeduz_emre @myESMO @ESMO_Open @OncoAlert @APCCC_Lugano #APCCC26 @BourlonMaite @nataliagandur @Silke_Gillessen @AOmlin @CaPsurvivorship @NehaVapiwala @piet_ost
9
22
560
Hatice Bölek retweeted
Seeing your mentee featured by @myESMO is something else. Dr. Hatice Bölek, top performers. That’s the work paying off. Proud. 🙌 @hatice_bolek @OncoAlert @Ankaratip1945 @AnkaraUni
📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST. 📍Onsite in Madrid + selected locations. ⏳Early fee ends 28 Apr. 🔗 Secure your seat: ow.ly/JWMq50YAGgM
1
6
44
2,175
Very happy to see this post by @myESMO.
📣 Validate your expertise with #ESMOExamination 2026 — 24 Oct, 13:00–15:30 CEST. 📍Onsite in Madrid + selected locations. ⏳Early fee ends 28 Apr. 🔗 Secure your seat: ow.ly/JWMq50YAGgM
3
1
34
1,558
Bladder Preservation Strategies in Muscle-Invasive Bladder Cancer @ASCO ascopubs.org/doi/10.1200/EDB…
1
5
13
735
Hatice Bölek retweeted
Phase 3 LITESPARK-011: Belzutifan + Lenvatinib vs Cabozantinib in pretreated metastatic clear cell renal cancer #GU25 shows +ve PFS HR 0.75 , OS HR 0.85 (non-significant), ⬆️ RR 53% vs 40%, G3+ TRAEs 72% vs 66%. Cabozantinib is hard to beat making this a standard of care. Using the most active drugs first rather than sequencing is debatable, but not all patients can sequence. We still don’t have significant OS post in IO refractory RCC @OncoAlert
37
4
85
6,543
Huge congrats to brilliant mentees @hatice_bolek @coskunyazgann and mente/mentor @yekeduz_emre Big thanks to @DrChoueiri @montypal @BradMcG04 and @DrRanaMcKay for their outstanding contributions, guidance, and support! 🔑IO rechallenge + VEGF TKI no survival gain in mRCC. @OncJournal @OncoAlert @Ankaratip1945 @AnkaraUni @IKCCorg @kidneycan @KidneyCancer @Uromigos doi.org/10.1093/oncolo/oyaf4…
4
31
3
111
9,361
Proud mentor moment. Heartfelt congrats, Hatice! This success is not luck. The future is bright! @myESMO @hatice_bolek @onkolojidernegi
1
11
650
It was a great experience to participate in the @myESMO Preceptorship on Prostate Cancer and to present a case in the session chaired by my mentor, @DrYukselUrun If you haven’t attended before, you should definitely consider joining next year.
1
20
770